Cargando…

The cognitive profile of type 1 Gaucher disease patients

BACKGROUND: The absence of neurological symptoms and signs is traditionally considered mandatory for a diagnosis of type 1 Gaucher disease (GD1), but in recent years many reports have emerged on neurological manifestations in GD1 patients. Nevertheless, it has been unclear whether cognitive deficits...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biegstraaten, Marieke, Wesnes, Keith A., Luzy, Cécile, Petakov, Milan, Mrsic, Mirando, Niederau, Claus, Giraldo, Pilar, Hughes, Derralynn, Mehta, Atul, Mengel, Karl-Eugen, Hollak, Carla E. M, Maródi, László, van Schaik, Ivo N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470680/ https://www.ncbi.nlm.nih.gov/pubmed/22350617 http://dx.doi.org/10.1007/s10545-012-9460-7

Ejemplares similares

Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
por: van Dussen, Laura, et al.
Publicado: (2014)

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
por: Arends, Maarten, et al.
Publicado: (2017)

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
por: van Dussen, Laura, et al.
Publicado: (2014)

Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Poikilothermia in a 38-year-old Fabry patient
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study
por: Cox, Timothy M, et al.
Publicado: (2012)

Cardiopulmonary assessment of patients diagnosed with Gaucher’s disease type I
por: Bjelobrk, Marija, et al.
Publicado: (2021)

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2016)

Peripheral neural response and sex hormones in type 1 Gaucher disease
por: Lakočević, Milan B., et al.
Publicado: (2020)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Immunoglobulin Heavy Chain Gene Rearrangements in Patients with Gaucher Disease
por: Rodić, Predrag, et al.
Publicado: (2018)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease
por: Yildiz, Yildiz, et al.
Publicado: (2013)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Quality of life in patients with Fabry disease: a systematic review of the literature
por: Arends, Maarten, et al.
Publicado: (2015)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease1
por: Hughes, Derralynn, et al.
Publicado: (2007)

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
por: Hughes, Derralynn A, et al.
Publicado: (2015)

Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study()()
por: McNeill, Alisdair, et al.
Publicado: (2013)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

In-depth phenotyping for clinical stratification of Gaucher disease
por: D’Amore, Simona, et al.
Publicado: (2021)

Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease
por: Giraldo, Pilar, et al.
Publicado: (2021)

An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
por: Hollak, Carla EM
Publicado: (2012)

Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Corrigendum to “Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study” [Mol. Genet. Metab. 109 (2013) 221–223]
por: McNeill, Alisdair, et al.
Publicado: (2014)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula
por: Giraldo, Pilar, et al.
Publicado: (2012)

The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
por: Schuller, Y., et al.
Publicado: (2015)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey
por: Mengel, Eugen, et al.
Publicado: (2020)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Recommendations on the follow‐up of patients with Gaucher disease in Spain: Results from a Delphi survey
por: Giraldo, Pilar, et al.
Publicado: (2022)

Identification of risk features for complication in Gaucher’s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease
por: Andrade-Campos, Marcio M., et al.
Publicado: (2020)

Scoring system to facilitate diagnosis of Gaucher disease
por: Mehta, Atul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_38fihdvf2m66idcmrh3lvve1j9